# Exeliom Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/exeliom-biosciences

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.exeliombio.com
- Total disclosed funding: $14M
- Latest round: Series A (Apr 28, 2025)
- Investors on record: 9

## About

Exeliom Biosciences focuses on developing innovative immunomodulation therapies by leveraging the NOD2 pathway to enhance immune responses, particularly for patients with various immune-related diseases.Exeliom Biosciences, founded in 2016, is a biotechnology company based in Paris, France, specializing in immunomodulation. The company was co-founded by Benjamin Hadida and Harry Sokol. In October 2025, Exeliom Biosciences raised EUR 2.85 million in series A funding led by returning investor Biocodex, with participation from other returning investors Crescent Enterprises Venture Capital and UI Investissement. New investor Forepont Capital Partners also participated in the round. Exeliom specializes in innovative immunomodulation solutions, focusing on leveraging the NOD2 pathway to develop therapies addressing various disease areas. Their flagship product, EXL01, uses microbiome-based approaches to modulate immune responses, particularly enhancing macrophage polarization. Exeliom primarily markets its products in North America and Europe, targeting healthcare providers and research institutions aiming for improved treatment outcomes in patients with immune-related conditions.Exeliom's revenue model is structured around strategic partnerships and collaborations with healthcare institutions and pharmaceutical companies, facilitating the distribution of their products. Transactions typically occur through B2B arrangements, with clients engaging in long-term agreements for the supply of EXL01 and related services. The company positions its offerings as premium solutions within the immunotherapy market, reflecting the advanced nature of their technology and its value to end-users. The company plans to utilize the October 2025 funding to advance Phase 2 clinical trials of EXL01 in cancer and infectious diseases.

## Funding rounds

- Series A, Apr 28, 2025, $4.5M — UI Investissement, Crescent Enterprises Venture Capital, Biocodex, Forepont Capital Partners
- Series A, Jun 14, 2023, $3.8M — Auriga Partners, UI Investissement, Crescent Enterprises, Capital Grand Est, Biocodex
- Series A, Aug 11, 2021, $1.3M — Auriga Partners, Sofimac Innovation, Capital Grand Est, Biocodex
- Series A, Dec 11, 2018, $4M — Auriga Partners, Sofimac Innovation, Capital Grand Est, Biocodex, INRAE

## Investors

- Auriga Partners (https://capitalatlas.ai/funds/auriga-partners) — Series A
- Sofimac Innovation (https://capitalatlas.ai/funds/sofimac-innovation) — Series A
- Capital Grand Est (https://capitalatlas.ai/funds/capital-grand-est) — Series A
- Biocodex — Series A
- INRAE — Series A
- UI Investissement (https://capitalatlas.ai/funds/ui-investissement) — Series A
- Crescent Enterprises — Series A
- Crescent Enterprises Venture Capital (https://capitalatlas.ai/funds/crescent-enterprises-venture-capital) — Series A
- Forepont Capital Partners (https://capitalatlas.ai/funds/forepont-capital-partners) — Series A